GC Green Cross MS Receives Approval for Dengue Virus Rapid Diagnostic Kit
GENEDIA W Dengue NS1 Ag and GENEDIA W Dengue IgM/IgG Ab obtain export approval from Ministry of Food and Drug Safety
SEOUL – GC Green Cross MS announced on the 18th that it has received export approval for its new diagnostic kit designed to detect the dengue virus. Developed using a similar principle to the successful COVID-19 rapid diagnostic kit, this advanced technology allows for the quick and accurate diagnosis of dengue fever within just 20 minutes using a blood sample.
One notable feature of this diagnostic kit is its ability to effectively diagnose all four serotypes of the dengue virus. In comparison to other competing products, GC MS has demonstrated higher sensitivity and accuracy through extensive clinical sample testing.
Dengue fever, a viral febrile disease transmitted primarily by the Aedes aegypti mosquito, is prevalent in tropical and subtropical regions, much like the Zika virus. With the increasing global warming and climate change, the number of dengue fever cases has been on the rise.
GC MS officials are optimistic about the growth potential of the mosquito-borne infection virus diagnostic kit market, particularly in regions such as Southeast Asia and South America, where the dengue virus has spread rapidly. “We anticipate rapid sales expansion in this market with the approval of our export license,” an official stated. Furthermore, GC MS is actively engaged in developing diagnostics for other mosquito-borne infectious diseases in line with market demands.
With this recent accomplishment, GC Green Cross MS aims to play a significant role in combating mosquito-borne diseases and contributing to public health worldwide.
Reporter: Jang Eun-pa
[비즈니스포스트] GC Green Cross MS received approval for a dengue virus rapid diagnostic kit from the Ministry of Food and Drug Safety.
GC Green Cross MS announced on the 18th that it has received export approval for the ‘GENEDIA W Dengue NS1 Ag’ antigen test and the ‘GENEDIA W Dengue IgM/IgG Ab’ antibody test.
▲ GC Green Cross MS announced on the 18th that it has received approval for a diagnostic kit related to the dengue fever virus from the Ministry of Food and Drug Safety. The picture shows the approved diagnostic kit.
The dengue fever diagnostic kit developed this time uses a similar principle to the rapid COVID-19 diagnostic kit familiar to users.
It can diagnose dengue fever within 20 minutes through a blood sample and is characterized by the ability to diagnose all four dengue virus serotypes.
GC MS explained, “In in-house clinical sample testing, we confirmed higher sensitivity and accuracy compared to other companies.”
Dengue fever, like Zika virus, is a representative viral febrile disease transmitted by Aedes aegypti mosquitoes mainly in tropical and subtropical regions. Recently, the number of dengue fever patients has been increasing due to global warming and climate change. .
A GC MS official said, “With the number of infected people worldwide increasing rapidly due to the recent spread of the dengue virus, a mosquito-borne disease, mainly in Southeast Asia and South America, we expect rapid sales expansion in the mosquito. – borne infection virus diagnostic kit market by obtaining this export license “Follow-up product development for mosquito-borne infectious diseases other than dengue fever is underway,” he said. Reporter Jang Eun-pa
#Green #Cross #receives #approval #dengue #fever #rapid #diagnostic #kit #Ministry #Food #Drug #Safety
